Home/Filings/4/0000899243-20-024396

4//SEC Filing

Pillar Invest Corp 4

Accession 0000899243-20-024396

CIK 0000861838other

View on SEC.gov Company Profile

Filed

Sep 3, 8:00 PM ET

Accepted

Sep 4, 7:01 PM ET

Size

20.5 KB

Accession

0000899243-20-024396

Insider Transaction Report

Form 4

Period: 2020-04-17

IDERA PHARMACEUTICALS, INC.IDRA

Pillar Invest Corp

Director10% Owner

Transactions

Other
Common Stock
2020-04-17−103,891→ 1,288,368 total(indirect: By Pillar Pharmaceuticals 6, L.P. See Footnotes)
Other
Common Stock
2020-04-17−46,304→ 5,427,697 total(indirect: By Foundation)

Holdings

Common Stock
(indirect: By Pillar Pharmaceuticals III, L.P. See Footnote)
29,998
Common Stock
(indirect: By Youssef El Zein See Footnote)
6,724
Common Stock
(indirect: By Pillar Pharmaceuticals I, L.P. See Footnote)
21,100
Common Stock
(indirect: By Pillar Pharmaceuticals IV, L.P. See Footnote)
1,000
Common Stock
(indirect: By Pillar Pharmaceuticals V, L.P. See Footnote)
25,000
Common Stock
(indirect: By Abude Umari See Footnotes)
190,117
Common Stock
(indirect: By Pillar Pharmaceuticals II, L.P. See Footnote)
20,820

Pillar Partners Foundation, L.P.

10% Owner

Transactions

Other
Common Stock
2020-04-17−46,304→ 5,427,697 total(indirect: By Foundation)
Other
Common Stock
2020-04-17−103,891→ 1,288,368 total(indirect: By Pillar Pharmaceuticals 6, L.P. See Footnotes)

Holdings

Common Stock
(indirect: By Abude Umari See Footnotes)
190,117
Common Stock
(indirect: By Pillar Pharmaceuticals V, L.P. See Footnote)
25,000
Common Stock
(indirect: By Pillar Pharmaceuticals I, L.P. See Footnote)
21,100
Common Stock
(indirect: By Pillar Pharmaceuticals III, L.P. See Footnote)
29,998
Common Stock
(indirect: By Pillar Pharmaceuticals IV, L.P. See Footnote)
1,000
Common Stock
(indirect: By Pillar Pharmaceuticals II, L.P. See Footnote)
20,820
Common Stock
(indirect: By Youssef El Zein See Footnote)
6,724

Pillar Pharmaceuticals 6, L.P.

10% Owner

Transactions

Other
Common Stock
2020-04-17−103,891→ 1,288,368 total(indirect: By Pillar Pharmaceuticals 6, L.P. See Footnotes)
Other
Common Stock
2020-04-17−46,304→ 5,427,697 total(indirect: By Foundation)

Holdings

Common Stock
(indirect: By Pillar Pharmaceuticals II, L.P. See Footnote)
20,820
Common Stock
(indirect: By Pillar Pharmaceuticals V, L.P. See Footnote)
25,000
Common Stock
(indirect: By Pillar Pharmaceuticals I, L.P. See Footnote)
21,100
Common Stock
(indirect: By Pillar Pharmaceuticals III, L.P. See Footnote)
29,998
Common Stock
(indirect: By Pillar Pharmaceuticals IV, L.P. See Footnote)
1,000
Common Stock
(indirect: By Youssef El Zein See Footnote)
6,724
Common Stock
(indirect: By Abude Umari See Footnotes)
190,117

Umari Abude

10% Owner

Transactions

Other
Common Stock
2020-04-17−46,304→ 5,427,697 total(indirect: By Foundation)
Other
Common Stock
2020-04-17−103,891→ 1,288,368 total(indirect: By Pillar Pharmaceuticals 6, L.P. See Footnotes)

Holdings

Common Stock
(indirect: By Pillar Pharmaceuticals IV, L.P. See Footnote)
1,000
Common Stock
(indirect: By Pillar Pharmaceuticals II, L.P. See Footnote)
20,820
Common Stock
(indirect: By Pillar Pharmaceuticals III, L.P. See Footnote)
29,998
Common Stock
(indirect: By Pillar Pharmaceuticals V, L.P. See Footnote)
25,000
Common Stock
(indirect: By Abude Umari See Footnotes)
190,117
Common Stock
(indirect: By Pillar Pharmaceuticals I, L.P. See Footnote)
21,100
Common Stock
(indirect: By Youssef El Zein See Footnote)
6,724

ZEIN YOUSSEF EL

Director

Transactions

Other
Common Stock
2020-04-17−103,891→ 1,288,368 total(indirect: By Pillar Pharmaceuticals 6, L.P. See Footnotes)
Other
Common Stock
2020-04-17−46,304→ 5,427,697 total(indirect: By Foundation)

Holdings

Common Stock
(indirect: By Pillar Pharmaceuticals III, L.P. See Footnote)
29,998
Common Stock
(indirect: By Youssef El Zein See Footnote)
6,724
Common Stock
(indirect: By Abude Umari See Footnotes)
190,117
Common Stock
(indirect: By Pillar Pharmaceuticals II, L.P. See Footnote)
20,820
Common Stock
(indirect: By Pillar Pharmaceuticals IV, L.P. See Footnote)
1,000
Common Stock
(indirect: By Pillar Pharmaceuticals I, L.P. See Footnote)
21,100
Common Stock
(indirect: By Pillar Pharmaceuticals V, L.P. See Footnote)
25,000

Footnotes (4)

[F1]On April 17, 2020, Pillar Partners Foundation, L.P. ("Pillar Foundation") distributed in-kind, without consideration, 46,304 shares of Common Stock to Abude Umari, in accordance with his pro rata interest in Pillar Foundation. This distribution was made in accordance with the exemptions under Rule 16a-9(a) and Rule 16a-13 of the Securities Exchange Act of 1934, as amended.
[F2]On April 17, 2020, Pillar Pharmaceuticals 6, L.P. ("Pillar 6") distributed in-kind, without consideration, 103,891 shares of Common Stock to Abude Umari, in accordance with his pro rata interest in Pillar 6. This distribution was made in accordance with the exemptions under Rule 16a-9(a) and Rule 16a-13 of the Securities Exchange Act of 1934, as amended.
[F3]Pillar Invest Corporation ("Pillar GP") is the general partner of Pillar Pharmaceuticals I, L.P., Pillar Pharmaceuticals II, L.P., Pillar Pharmaceuticals III, L.P., Pillar Pharmaceuticals IV, L.P., Pillar Pharmaceuticals V, L.P., Pillar 6 and Pillar Foundation (collectively, the "Pillar Funds"). Youssef El Zein and Abude Umari are directors of Pillar GP. Each of Pillar GP, Mr. El Zein and Mr. Umari disclaims Section 16 beneficial ownership of the securities beneficially owned by the Pillar Funds and this report shall not be deemed an admission that any of Pillar GP, Mr. El Zein or Mr. Umari is the Section 16 beneficial owner of any such securities, except to the extent of its or his pecuniary interest therein, if any, by virtue of its or his ownership interest in the Pillar Funds or Pillar GP, as applicable.
[F4]Includes the shares received by Mr. Umari in the distributions reported in footnotes (1) and (2).

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

IDERA PHARMACEUTICALS, INC.

CIK 0000861838

→

Entity typeother

IncorporatedCayman Islands

Related Parties

filerCIK 0001534428

Filing Metadata

Form type: 4
Filed: Sep 3, 8:00 PM ET
Accepted: Sep 4, 7:01 PM ET
Size: 20.5 KB

View on SEC.gov